Rhythm Pharmaceuticals, Inc.'s SEC filings document a commercial-stage biopharmaceutical company whose disclosures center on IMCIVREE (setmelanotide), MC4R pathway rare-disease indications and related clinical and regulatory milestones. Recent Form 8-K reports include operating results, product-revenue commentary, FDA and European regulatory updates for acquired hypothalamic obesity, and trial disclosures for programs such as TRANSCEND and EMANATE.
Rhythm's proxy materials and governance filings disclose board composition, director elections, executive compensation, equity awards and shareholder voting matters. Other current reports record director changes, Regulation FD materials, presentations and press releases, tying corporate governance and public-company reporting to the company's rare neuroendocrine disease portfolio.
Rhythm Pharmaceuticals reported strong top-line growth but continued losses for the quarter ended March 31, 2026. Net product revenue rose to $60.1 million from $37.7 million, driven by IMCIVREE sales in the U.S. and internationally. Total revenue was $60.1 million after a prior-year license revenue reduction.
The company posted a net loss of $55.6 million, wider than $49.5 million a year earlier, with higher research and development and selling, general and administrative expenses. Cash, cash equivalents and short-term investments were $340.6 million, and management believes this will fund operations for at least the next 24 months. A deferred royalty obligation related to a royalty financing totaled $108.5 million, and Series A convertible preferred stock stood at $114.7 million. Common shares outstanding were 68.4 million as of March 31, 2026, with additional potential dilution from equity awards and convertible preferred stock.
Rhythm Pharmaceuticals reported strong commercial momentum in the first quarter of 2026 as it launched IMCIVREE for acquired hypothalamic obesity in the U.S. and secured European Commission Marketing Authorization for the same indication. More than 150 patient start forms were received in the first six weeks after U.S. FDA approval on March 19, 2026.
Net product revenue from global IMCIVREE sales reached $60.1 million for the quarter, up from $37.7 million a year earlier. Revenue of $36.9 million came from the U.S. and $23.2 million from outside the U.S. The company recorded a net loss attributable to common stockholders of $56.7 million, or $(0.83) per share.
Rhythm ended March 31, 2026 with $340.6 million in cash, cash equivalents and short-term investments and expects this to fund operations for at least 24 months. For full-year 2026, it projects $385–$415 million in Non-GAAP operating expenses as it advances setmelanotide, bivamelagon and RM-718 across multiple late-stage and early-stage trials.
Rhythm Pharmaceuticals Inc shows a Schedule 13G filing reporting that Vanguard Capital Management beneficially owned 3,432,949 shares of common stock, representing 5.02% of the outstanding class as of 03/31/2026.
The filing lists sole dispositive power over 3,432,949 shares and sole voting power for 465,124 shares. The report is signed by Vanguard's Head of Global Fund Administration on 04/30/2026.
Rhythm Pharmaceuticals is holding a virtual 2026 Annual Meeting on June 24, 2026 at 2:00 p.m. Eastern to vote on key governance matters. Stockholders will elect two Class III directors, ratify Ernst & Young LLP as auditor for 2026, and approve an advisory Say-on-Pay vote on executive compensation.
Holders of 68,530,107 shares of common stock as of April 27, 2026, and certain Series A Convertible Preferred Stock holders subject to conversion limits, may vote online, by phone, mail, or during the webcast. The company highlights its classified board, independent committees, and expanding ESG and human capital initiatives, including low 2025 employee turnover and recognition as a top workplace.
Rhythm Pharmaceuticals EVP exercises restricted stock units into shares
Executive Vice President and Head of International Yann Mazabraud exercised restricted stock units that convert into common stock of Rhythm Pharmaceuticals. On April 1, 2026, he converted 10,375 and 2,500 restricted stock units into common shares at an exercise price of $0.00 per share.
Following these derivative exercises, his direct holdings increased to 66,030 shares of common stock. Each restricted stock unit represents a contingent right to receive one share of common stock and vests in four annual installments between April 2024 and April 2028, with no expiration date stated for the units.
RHYTHM PHARMACEUTICALS, INC. director Kimberly J. Popovits received equity-based compensation on April 1, 2026. She was granted 6,808 Restricted Stock Units, each representing a right to receive one share of common stock.
The RSUs vest in three equal installments of 33% on April 1, 2027, April 1, 2028, and April 1, 2029, provided she continues in service. She was also granted 10,257 stock options with an exercise price of $88.12 per share, vesting in three substantially equal annual installments and expiring on March 31, 2036.
RHYTHM PHARMACEUTICALS, INC. director Kimberly J. Popovits has filed an initial Form 3, which is a statement of beneficial ownership for insiders. This filing lists her as a director of the company but does not report any stock transactions or derivative positions.
Rhythm Pharmaceuticals reported changes to its Board of Directors. On April 1, 2026, the Board elected industry veteran Kimberly J. Popovits as a non-employee Class II director, with her term running until the 2028 annual meeting of stockholders. She will receive compensation under the existing non-employee director policy and enter the company’s standard indemnification agreement.
On the same date, long-serving director Edward T. Mathers resigned from the Board, with the company stating his resignation was not due to any disagreement over operations, policies or practices. Rhythm highlights its commercial-stage rare disease focus built around IMCIVREE (setmelanotide), an MC4R agonist approved for specific rare obesity indications in the United States, European Union and United Kingdom.
The Vanguard Group filed Amendment No. 3 to a Schedule 13G/A reporting beneficial ownership of 0 shares (0%) of Rhythm Pharmaceuticals Inc common stock following an internal realignment. The filing states certain Vanguard subsidiaries will report holdings separately in reliance on SEC Release No. 34-39538. The filing lists the issuer address as 500 Boylston Street, Boston, MA and is signed by Ashley Grim on 03/27/2026.